Does a Suspicious PET Finding — Always Need a Biopsy?

Increased uptake means the scanner detected higher metabolic activity in that area. It does not mean cancer. Many things cause increased uptake: infection, inflammation, healing after surgery or radiotherapy, and some completely normal organs — the brain, the heart, and parts of the bowel all show uptake that has nothing to do with cancer. The report is the radiologist's observation; the interpretation is your oncologist's job, and it depends on everything else they know about you.

PET scans have a known rate of both false positives and false negatives, and that rate varies by cancer type and location. ASCO and ESMO guidance consistently emphasises that PET findings require clinical correlation precisely because no scan is diagnostic alone. A finding that lights up brightly may not be cancer; a site that shows no uptake may still contain disease. This is why tissue remains the standard for diagnosis whenever a treatment decision is at stake.

In most cases where watchful waiting is recommended, the pattern of the finding is the reason for it. A finding that is likely to represent inflammation or treatment effect is not made safer by an urgent biopsy — the biopsy itself carries real risk. The waiting period is appropriate only when your team has a clear reason for it and a clear endpoint: a date when you re-scan and reassess. Ask what they expect to see, and what you should do if anything changes before that date. If you do not have clear answers to both, say so.

That is a conversation worth having directly. Ask your oncologist to explain why biopsy is not the next step and what they are watching for instead. If you remain uncertain after that explanation, you are entitled to a second opinion at another centre, and a responsible oncologist will support that. Understand also that biopsies carry real risks — bleeding, infection, and sometimes a non-diagnostic result where the needle samples tissue beside the tumour rather than within it. The aim is the most informative and least harmful path, and sometimes those are in tension.

Yes, and this is a known limitation. If the needle samples tissue adjacent to the tumour rather than within it, the result can come back normal even when cancer is present. This is more likely when the finding is small, the site is technically difficult to reach, or the uptake pattern is irregular. Your team uses imaging guidance — CT or ultrasound — to direct the needle as precisely as possible. A negative biopsy does not always close the investigation; whether it does depends on how confident your team is that the right area was sampled.

A new finding is not automatically worse news than a stable one — but it does need to be explained. New findings go through the same decision process: does this pattern fit a known benign cause, or does it need investigation? What matters most is that someone is actively following it and has told you what the plan is. If a new finding has appeared in your report and no one has discussed it with you, call and ask for that conversation before your next scheduled appointment.